Patent · US Expired

Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers

US6544947B2 · kind B2 · utility

21Cited by
0References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 17, 2001
Grant dateApr 8, 2003
Priority date—
Expiry dateJul 17, 2021

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/4853
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compositions and methods for regulating angiogenic activity wherein the compositions comprise cancer markers including kallikreins such as prostate-specific antigen (PSA), serine protease homologs, or active fragments thereof are provided. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, PSA, PSA homologs, and inhibitory fragments thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.